Newomics.

A nine-person lab in Berkeley is quietly upgrading the world's mass spectrometers.

Walk into the building at 8th Street in Berkeley and you will not find a sprawling biotech campus. You will find a small team, a clean room, and a product that ships in a box smaller than a toaster. Newomics makes the part of a mass spectrometer almost nobody talks about: the front end, where a liquid sample becomes a fine spray of charged molecules that the instrument can actually weigh. Get that step wrong and the most expensive analyzer in the lab goes half-blind. Newomics exists because, for a long time, that step was a compromise.

The pitch is refreshingly unglamorous. Labs have already spent six and seven figures on mass spectrometers from Thermo, Bruker, Agilent and Waters. Newomics does not ask them to spend it again. It sells a source and an emitter chip that bolt onto what they own and pull more signal out of the same sample. In a field that loves to announce revolutions, Newomics sells an upgrade. That turns out to be the more interesting story.

Sensitivity or robustness. For years you had to pick one.

Here is the tension that runs through everything Newomics does. There are two ways to feed a sample into a mass spectrometer. Nanoflow gives you exquisite sensitivity - it can read molecules present in trace amounts - but it is famously temperamental, clogging and drifting and demanding a skilled hand. Microflow is sturdy and reproducible, the workhorse of any high-throughput lab, but it throws away sensitivity to get there.

Most labs accepted the trade. They ran microflow when they needed reliability across hundreds of samples, and nanoflow when they needed to see the faint stuff, and they suffered the consequences of whichever one they chose. The faint stuff, of course, is exactly where the interesting biology hides - the early biomarker, the rare protein, the single cell. Asking a scientist to choose between seeing it and trusting their results is, when you think about it, a strange thing to ask. Newomics thought so too.

Don't choose. Split the flow across many nozzles.

The idea came out of Lawrence Berkeley National Laboratory, where Daojing Wang spent years as a career scientist before deciding the technology deserved a company rather than a paper. The insight is almost mechanical in its simplicity: take a microflow stream and divide it across an array of tiny nozzles etched into silicon. Each nozzle sees only a sliver of the total flow, so each one sprays at effectively nanoflow rates - sensitivity - while the device as a whole handles a robust microflow volume - reliability. The compromise dissolves.

Wang founded Newomics in 2011 and, with co-founder Pan Mao, set about turning a multinozzle emitter array - an invention that won a 2012 R&D 100 Award, the prize sometimes called the Oscars of invention - into something a stranger could plug in and use. That is a harder problem than it sounds. A clever device in a national lab is one thing; a product that survives 300 plasma injections without a technician babysitting it is another. The bet was that they could cross that gap.

From a lab invention to a shipping product.

Four pieces of hardware doing one job well.

Newomics' catalog is small and deliberate. Everything points at the same goal: get more out of the molecules already in the vial.

The numbers that make skeptics look twice.

Claims about sensitivity are cheap. Newomics puts figures next to them - the kind a lab manager can test on a Tuesday.

Then there are the names. Regeneron showed up as an early adopter. Thermo Fisher Scientific - one of the giants whose instruments Newomics upgrades rather than replaces - signed two co-marketing agreements, a vote of confidence from the incumbent. Pharmaceutical and academic labs round out the customer base, and the work has appeared in peer-reviewed publications, including a study on native N-glycan analysis. For a nine-person company, that is a lot of credible company.

Omics solutions for precision medicine.

The phrase Newomics keeps returning to is precision medicine - the idea that treatment should be tuned to the molecules in a particular patient rather than the averages of a population. That ambition runs straight into the sensitivity problem. The molecular signals that distinguish one patient from another are often faint, present in tiny volumes, hiding inside single cells. You cannot personalize what you cannot detect.

So Newomics frames its hardware as infrastructure for that future. The same emitter that helps a pharma lab quantify a drug can help researchers chase Alzheimer's biomarkers, check food for contaminants, or run forensic analysis. The applications fan out, but the through-line holds: make the invisible visible, reliably, at a pace a real lab can sustain. ISO 9001:2015 on the wall is the unromantic proof that they take the “reliably” part seriously.

Single cells, faint signals, and the next decade of reading biology.

Biology keeps shrinking its questions. Where labs once studied populations of cells, they now want answers from individual ones, where the amount of material is almost nothing and the demand for sensitivity is almost everything. That is the direction Newomics has been pointed at all along. A front end that delivers nanoflow sensitivity with microflow reliability is not a niche convenience in that world - it is closer to a prerequisite.

Whether a nine-person company can scale into that future is the open question, and the honest one. The technology has the awards, the early customers, the vendor blessing and the funding. What it needs now is reach. That is what the Series B was for.

Back at 8th Street.

The lab in Berkeley still fits in one building. The team is still small. But the box that ships out the door now carries something the field spent years insisting you could not have: sensitivity and robustness, together, on a chip. The compromise that every mass spec lab quietly lived with is, for the labs that have plugged Newomics in, simply gone. Not announced as a revolution. Just shipped, in a box smaller than a toaster, to people who needed to see more.

See it in action.

Links & sources.